Mylan, Sunovion Reach Terms In Xopenex Patent Fight

Law360, New York (May 29, 2012, 5:50 PM EDT) -- Mylan Inc. said Tuesday it had settled a patent fight with Sunovion Pharmaceuticals Inc. over the asthma drug Xopenex, in a deal that will allow Mylan to continue selling its own version of the drug and release it from paying an $18 million damages award.

The settlement ends a protracted fight between the companies that started in 2006, when Sunovion alleged that Mylan had willfully infringed five patents for the medication. In 2008, Mylan sued Sunovion, seeking a declaratory judgment labeling a separate patent covering the...
To view the full article, register now.